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Abstract
Background: Myxomatous mitral valve prolapse is a common cardiac abnormality. Morbus Barlow is characterized
by excess myxomatous leaflet tissue, bileaflet prolapse or billowing, chordae elongation and annular dilatation with
or without calcification. Extensive myxoid degeneration with destruction of the normal three-layered leaflet tissue
architecture is observed histologically in such patients. Autosomal dominant inheritance with an age and sex-dependent
expression has long been recognised. This review explores the current understanding of the genetics of bileaflet
prolapse, with a focus on genetic analysis and the role for echocardiographical screening of the first degree
relatives of affected patients.
Methods: Systematic literature searches were performed using PubMed and Embase up to September 2017. In
Disse et al.’s study (study one) first degree relatives of 25 patients with Morbus Barlow who underwent mitral
valve repair were screened for bileaflet valve prolapse. In Nesta et al.’s study one family with three living
generations of 43 individuals with 9 confirmed cases of MVP was screened. Genotyping was performed in four families
for 344 microsatellite markers from Chromosome 1 to 16.
Results: In study one, autosomal dominant inheritance was shown in four pedigrees. Genome-wide linkage analysis of
the most informative pedigree (24 individuals, three generations) showed a significant linkage for markers mapping to
chromosome 16p. Linkage to this locus was confirmed in a second family within the same study, but was excluded in
the remaining two pedigrees. In study two an autosomal dominant locus was mapped to chromosome 13. 8 of the 9
individuals affected were found to suffer from bileaflet prolapse.
Conclusions: Barlow’s disease is a heritable trait but the genetic causes remain largely elusive. Ch16p11.2-p12.1 is the
only locus proven to be associated with bileaflet prolapse. Locus 13.q31.3-q32.1 was shown to cause bileaflet as well as
posterior leaflet prolapse. This review intends to make physicians aware of genetic causes of myxomatous mitral valve
prolapse, thereby emphasising the importance of cardiological examination of first-degree relatives of patients with
Morbus Barlow. Integrated and more comprehensive studies are needed for identification of genes involved in this
heterogenic disease. Further genomic studies may facilitate more individualised and accurate risk assessment and may
help to develop possible preventive stategies for patients in the future.
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Background
Myxomatous mitral valve disease (MMVD) is a common
cardiac anomaly which affects up to 5% of the general
population [1]. It is characterized by a wide spectrum of
clinical and electrocardiographic features, ranging from
no symptoms (in the vast majority of individuals) to
symptomatic mitral regurgitation, endocarditis, cerebral
embolism and arrhythmias [1]. The myxomatous
degeneration process often affects the whole mitral valve
and therefore patients with Barlow’s disease present
frequently with complex valve pathology and dysfunc-
tion, which is mostly multi-segmental. There is no
current consensus in terms of the true definition of
Barlow’s disease. Cardiologists diagnose Morbus Barlow
when bileaflet prolapse is present, regardless of its ex-
tent. Conversely, surgeons refer to Barlow’s disease in
the presence of extensive myxoid degeneration, chordae
elongation and annular dilatation with prolapse of one
or both mitral valve leaflets. The histological changes of
myxomatous degeneration are well understood. They
include accumulation of glycosaminoglycans, collagen
fragmentation, disorganisation of the extracellular matrix
(ECM) and increased expression of proteolytic enzymes.
However, the molecular pathways leading to MMVD are
yet to be clarified [2].
Clinical presentation
MMVD is usually to be found in adults in 5th and 6th
decades of life. Physicians often hear ‘murmurs’ in
asymptomatic patients who are then followed for de-
cades before being referred to a cardiologist or a cardiac
surgeon. Referral is usually triggered by the development
of symptoms. Typically patients with MMVD develop
atrial fibrillation, shortness of breath and fatigue accom-
panied by left ventricular dilatation or worsening of left
ventricular function. Pulmonary hypertension may be
present to varying degrees. Physical examination most
often shows a mid-systolic click and a mid to late
systolic murmur, reflecting the timing of prolapse in the
setting of excess tissue and chordal elongation [3].
Echocardiographic findings
Echocardiography is, and may always remain, the gold
standard tool for differentiation of degenerative mitral
valve disease. Patients with Barlow’s disease have a
characteristic echocardiographical appearance of the mi-
tral valve apparatus. The leaflets are usually thick, bulky,
elongated and distended. The chords are thickened and
elongated and often ‘mesh-like’ in nature. The annulus is
dilated (intercommissural distance of > 36 mm) in most
cases. Prolapse is often multi-segmental. In up to 40% of
patients, both leaflets are involved [4]. The insertion
point of the posterior mitral leaflet (PML) is often
displaced towards the left atrium, away from its normal
insertion in the atrio-ventricular groove, creating a cul-
de-sac at the base of the leaflet. The bodies of the bulky
leaflet segments often billow above the plane of the mi-
tral annulus. The free leaflet margins prolapse during
mid to late systole, in the setting of chordal elongation,
or in early systole if chordal rupture has already oc-
curred. Calcification of the annulus and of papillary
muscle tips may be present. In the late systole “papillary
muscle traction” causes the papillary muscle tip to be
drawn upward to the plane of the mitral annulus instead
of downward towards the apex, as is the normal motion
[5]. This may be demonstrated echocardiographically as
a left ventricular wall motion abnormality [6].
Histological findings
The degenerative process within the mitral valve has two
distinct histological phenotypes: diffuse myxomatous
degeneration (MMVD or so-called ‘Barlow’s’ disease)
and fibroelastic deficiency (FED) which is characterized
by thin, translucent leaflets without excessive leaflet
tissue. The pathological features of FED consist of both
qualitative and quantitative abnormalities in the
connective tissue structure. This includes deficiencies of
collagen, elastin and proteoglycans. The histological
hallmark of myxomatous mitral valve degeneration is
myxoid tissue infiltration resulting in destruction of the
three-layered leaflet architecture. Moreover, histological
examination reveals often-severe alterations in collagen
structure [7].
History of myxomatous mitral valve disease
Barlow initially described the syndrome characterised by
a late systolic murmur and non-ejection systolic click.
He and his colleagues performed cardiac catheterisation
and phonocardiography, confirming that these ausculta-
tory findings were due to mitral regurgitation occurring
in late systole. They emphasized that the condition they
were reporting was distinct from apical pan-systolic
murmurs with late systolic accentuation as a result of
mitral regurgitation [5]. In 1964, Segal and Likoff
reported late systolic “bulging” of the anterior mitral
leaflet associated with the onset of mitral regurgitation
[8]. In 1966, Barlow and Bosman reported on 4 patients
presenting with late mitral murmurs and mid-systolic
clicks in whom the whole posterior mitral leaflet
protruded extensively into the left atrium during systole.
They described the posterior mitral leaflet as
“aneurysmal” or “billowing.” [9]. Also in 1966, Criley and
colleagues performed cine-angiographic studies that
showed late systolic motion of large mitral leaflets into
the left atrium [5]. In 1968, mitral valve tissue was
excised from 3 patients with myxomatous disease who
underwent mitral valve replacement and was reported to
show severe myxomatous degeneration of the leaflets
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and chordae [5]. Also in 1968, Ehlers and associates
were the first to report left ventricular wall motion
abnormalities in MMVD [10]. They observed a “systolic
contraction ring” at the base of papillary muscles and
hypothesized that this could lift both papillary muscles
into the left ventricular cavity and towards the mitral
annulus during systole, causing the chordae to slacken.
In 1973, Liedtke and coworkers and Scampardonis and
colleagues independently reported a high incidence of
left ventricular “inflow wall” systolic motion abnormal-
ities in the region of the base of papillary muscles [11,
12]. Liedtke and coworkers also noted that in patients
with “mitral click syndrome” the papillary muscles
moved toward the mitral valve annulus in systole, rather
than towards the left ventricular apex [5].
Methods
Literature search and study selection
We conducted a systematic literature search using
Pubmed and Embase, including references published up
until September 2017. For this review, patients meeting
the ‘surgical’ definition of Barlow’s disease i.e. a high
degree of myxomatous degeneration with prolapse of
one or both leaflets, were of interest. The following key
words were screened: “Morbus Barlow”, “Barlow’s
disease”, “genetic findings”, “genetic pathways”, “bileaflet
prolapse”, “barlow mitral genetic”, “bileaflet mitral valve
genetic analysis”, “myxomatous valve disease” and
“myxomatous mitral valve”.
One reviewer performed the literature search. All rele-
vant studies were included if published in a peer-
reviewed journal and if the following inclusion criteria
were met (Fig. 1):
a) Affected individuals were diagnosed with
myxomatous mitral valve disease and diagnosis was
confirmed by histological examination or patients
were found to have bileaflet mitral valve prolapse by
echocardiography (i.e. involvement of the anterior
and posterior leaflet)
b) The patients had a non-syndromic MVP (mitral
valve prolapse)
c) Genetic analysis was performed
Proband selection
All patients with known syndromic diseases were
excluded from our review. Individuals with histological
proof of MMVD who underwent mitral valve surgery
and those with echocardiographic evidence of bileaflet
prolapse were selected for subsequent genetic analysis,
including their first-degree relatives. In the following
paragraphs, we briefly describe patient’s selection
process and methodology of the selected studies:
Chromosome 16 (MMVP1)
One recent study included families of 17 patients who
underwent mitral valve repair and had histological verifi-
cation of MMVD [13]. First degree relatives of these
Fig. 1 Trial enrollment showing the number of publications examining patients with myxomatous mitral valve disease who underwent genetic
screening and echocardiography or surgery up to 09/2017. Patients with syndromic MVP were excluded. Thus, 7 papers were included in the
further analysis
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patients were screened using echocardiography in a
double-blinded fashion to identify individuals with
MMVP. The subjects were considered affected whenever
the following criteria were met: (a) leaflet thickness >
5 mm, (b) a total leaflet displacement > 8 mm, and (c) late
systolic mitral valve insufficiency. Genotyping was
performed using 344 microsatellite markers from chromo-
somes 1 to 16.
Chromosome 13 (MMVP3)
Another study was carried out on one pedigree in a
family of Western European descent [14]. The proband
was a physician with diagnosed mitral valve prolapse.
His family of 46 members of 3 living generations, were
screened using echocardiography. “Classical” MVP was
diagnosed if leaflet displacement exceeded 2 mm and
maximal leaflet thickness was ≥ 5 mm. MVP was consid-
ered as “non-classical” if leaflet displacement exceeded
2 mm but maximal thickness was < 5 mm. Both echocar-
diographic variants were considered as MMVD positive.
Genotypic analysis were performed using polymorphic
microsatellite markers.
Chromosome 11 (MMVP2)
This analysis was performed using a single large
pedigree of 41 individuals in 5 generations of a family
of Western European descent [15]. The proband was
identified as a volunteer during a teaching course on
the topic of echocardiographic imaging. The subjects
were classified as having MVP if leaflet displacement
exceeded 2 mm. Patients were considered ‘indetermin-
ate’ when leaflet displacement was ≤ 2 mm but there
was evidence of either increased leaflet thickness, mitral
regurgitation, left atrial enlargement, valve-related
complications or disease progression over a period of
10 years. GeneHunter was used to perform genome
scan. Multipoint parametric analysis was performed
using 375 genetic markers and was confirmed by multi-
point non-parametric analysis. Analysis was performed
before the genome scanning to exclude coincident
linkage to MMVP1 in Chr.16.
X-linked-MVD (XMVD)
A large family of French origin was analyzed [16]. The
proband underwent aortic valve replacement due to
severe aortic regurgitation caused by myxomatous aortic
valve disease. His cousin had to undergo mitral valve
surgery due to mitral valve dystrophy. Based on two
affected patients, more than 300 family members were
screened by echocardiography and a subsequent genetic
study was performed using linkage analysis in 92
individuals [17, 18].
The role of TGF-β-signalling and increased oxidative stress
in MMVD
Two studies analyzed 70 samples of mitral valve tissue
which were collected during valve surgery [19, 20]. Half
of these samples were acquired from patients who were
diagnosed with MMVD by echocardiography and
confirmed during surgery. The diagnosis of MMVP was
verified by histopathological analysis of leaflet tissue.
The remaining 35 control samples were collected from
cardiac transplant recipients. Molecular changes in the
mitral valves were assessed by means of qRT-PCR
(quantitative real-time polymerase chain reaction),
Western blotting and immunocytochemistry, and were
compared between both subgroups [19, 20].
Results
Literature search and study characteristics
Based on our initial literature search, 172 potentially
relevant references published between 1966 and 2016
were identified and 78 abstracts were screened. After
exclusion of duplicate publications, a total of 160
citations were selected for full-text review. Full-text
review revealed 23 potentially eligible studies. 7 of these
met the necessary inclusion criteria and were selected
for our cumulative analysis (Table 1).
Echocardiographical findings
Figures 2, 3, 4, 5, 6 and 7.
Genetics of myxomatous mitral valve disease
Two loci of autosomal dominant inheritance causing
bileaflet prolapse have been identified in chromosomes
16 and 13 [14, 15]. An autosomal dominant inheritance
pattern for MVP was mapped to locus 11p15.4. Of note,
the anatomical changes in these cases were not uniform,
with 5 cases of bileaflet prolapse and 7 of isolated
posterior leaflet prolapse [15]. Structural changes in
filamin-A architecture caused by X-linked inheritance
were found to cause myxomatous valvular dystrophy of
the mitral and/or aortic valve combined with haemophilia
A [16]. An overview of the findings of the identified
studies is given in the following paragraphs.
Genetic findings in chromosome 16 (MMVP1)
Of the 17 families screened, 4 autosomal dominant pedi-
grees were identified [13]. Of these pedigrees, one was of
Ashkenazi Jewish and the remaining three of French
origin. Each pedigree had 5–9 affected relatives in 3–4
generations. Locus 16p12.1-p11.2 was identified in all af-
fected individuals. 25 (32%) of the 79 family members
screened using echocardiography were affected by MMVD
causing MVP (Figs. 2 and 6).
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Genetic findings in chromosome 13 (MMVP3)
A total of 43 family members were screened echocardio-
graphically and genetically [14]. Nine (21%) patients met
echocardiographic criteria of MVP, whilst 8 were
diagnosed with bileaflet prolapse (Figs. 4 and 6). A total
of 14 probands of this pedigree, including nine affected
individuals, were screened genetically. The MMVP3
gene was mapped to the long arm of chromosome 13
and demonstrated an autosomal dominant inheritance
pattern.
Genetic findings in chromosome 11 (MMVP2)
The pedigree analysis included 41 individuals in 5 gener-
ations of a family of Western European descent [15].
Echocardiograms and DNA were obtained from 28
(68%) subjects, of whom 12 individuals were diagnosed
with MVP. Five individuals had a bileaflet prolapse,
while the remaining subjects had an isolated posterior
leaflet prolapse (Figs. 3 and 6). MMVP2 gene, which was
revealed as a cause of mitral valve prolapse, was mapped
to chromosome 11p15.4 and demonstrated an autosomal
dominant inheritance pattern.
X-linked MVD (XMVD)
Two affected individuals who were scheduled for valve
surgery due to valvular dystrophy were also found to
suffer from a mild form of haemophilia A. A very thor-
ough screening of the above mentioned family, including
more than 300 individuals, revealed a total of 93 individ-
uals with symptomatic myxomatous mitral and/or aortic
valve disease. In all affected members the valvular dis-
ease was associated with a mild form of haemophilia A.
Moreover, we found an additional report on a patient
undergoing surgery due to severe aortic valve regurgita-
tion who was diagnosed with haemophilia A. This pa-
tient was also of French origin and had shared ancestry
with the aforementioned family. A genealogical approach
identified this ancestor as having lived in the eighteenth
century, In this special family a total of 9 affected
Table 1 Gives an overview of study designs and methods
Disse et al. [13] Freed et al.
[15]
Nesta et al. [14] Monteleone et al. [18]
Lardeux et al. [17]
Kyndt et al. [16]
Hagler et al. [19] Thalji et al. [20]
No° of pedigrees
included
4 1 1 1 – –
No° of individuals
included
64 41 46 n/a (> 300) 48 22
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No° of pedigrees and individuals tested are displayed. Underlying valve disease for each gene defect/ study is shown. Study design (e.g. double-blinded echocardiography,
method used for genotyping) as well as in- and exclusion criteria are described
m male, MVP mitral valve prolapse, n/a not available, f female, MVR mitral valve regurgitation, No° number, AML anterior mitral leaflet, MMVP myxomatous mitral
valve prolapse, PML posterior mitral leaflet, qRT-PCR quantitative real-time polymerase chain reaction
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Fig. 4 Shows the severity of mitral regurgitation in affected patients
(i.e. positive genetic testing) with gene defect “MMVP 3”
Fig. 3 Shows the severity of mitral regurgitation in affected patients
(i.e. positive genetic testing) with gene defect “MMVP 2”
Fig. 5 The pie chart shows grade of MR from the studies examining
the X-linked mode of inheritance. The cumulative data of all 92
screened patients (i.e., echocardiography + genetic analysis) is
displayed. Data of genetically affected patients is not provided
Fig. 2 Shows the severity of mitral regurgitation in affected patients
(i.e. positive genetic testing) with gene defect “MMVP1”
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individuals with a co-existent valvular dystrophy and
haemophilia A were identified [16, 18]. Using linkage
analysis, the gene on chromosome Xq28 could be
mapped. A positional cloning approach revealed a muta-
tion in the FLNA gene in all affected family members.
The X-linked change in filamin A was found to promote
valvular dystrophy with an increase in anterior and
posterior leaflet thickness and length in all mutation posi-
tive individuals. A total of 18 patients were found to have
mitral valve regurgitation (Figs. 5 and 7). In affected male
individuals, mitral valvular dystrophy was found to be
more severe and was associated with a significant mi-
tral annular enlargement when compared to their fe-
male counterparts (Table 2).
Pathophysiological biomolecular pathways in MMVD
A recent study by Thalji and co-authors reported a
differing gene expression patterns in myxomatous versus
non-myxomatous mitral valves [20]. Transforming
growth factor beta (TGF-β) signalling was found to be
upregulated in myxomatous mitral valve tissue due to
increased ligand expression and depression of canonical
SMAD 2/3 signaling. Canonical bone morphogenetic
protein (BMP) and Wnt/ ß-catenin signalling pathways
were also found to be upregulated in MMVD and are
associated with increased matrix remodelling, “pro-cal-
cific” and pro-proliferative cellular responses. The
expression of all 3 TGF-β subtype transcripts was sig-
nificantly increased in the diseased mitral valve tissue
and this was confirmed using immunoblotting [21].
Histopathological analysis demonstrated activated im-
mune cells to be localised to the myxomatous mitral valve
tissue [20]. Furthermore, oxidative stress was found to be
significantly increased in the myxomatous mitral valves,
induced by the stimulation of Nox 2 and Nox 4 gene ex-
pression (coding for NAPDH oxidase catalytic subunits)
Fig. 6 Prolapse localization of all affected patients is shown. Patients were considered to be affected either if surgery was performed due to valve
regurgitation and myxomatous changes were confirmed by histological examination or if mitral valve prolapse with leaflet displacement of one
or both leaflets ≥ 2 mm and leaflet thickening were present in echocardiography
Fig. 7 gives an overview of prolapse localization in all patients screened, including relatives of affected patients
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[19]. This pathway may further contribute to the amplifi-
cation of TGF-ß signalling by SMAD 2/3 phosphorylation.
Recent in vitro studies using mitral leaflet specimens
obtained by surgical excision have shown that myxoma-
tous mitral valve changes might be pharmacologically
modifiable by angiotensin receptor 2 blockers, a process
which is based on TGF-ß modulation [21] (Table 3).
Discussion
The lack of a standardised definition of Barlow’s disease
made this review a challenge. We focussed on patients
with excessive myxomatous degeneration of the mitral
valve, chordae elongation, annular dilatation and presence
of prolapse of one or both leaflets of the mitral valve, as
per the ‘surgical’ definition of Barlow’s syndrome. The aim
of this review is to make physicians aware of MMVD as a
heritable trait. Relatives of patients with surgically-
confirmed Barlow’s disease may benefit from cardiological
examination and follow-up. Our systematic literature
review demonstrates genetic heterogeneity of MMVD
with linkage to chromosomes 11, 13, 16 and the X
chromosome. Moreover, the pathophysiological impact of
increased transforming growth factor-ß expression and of
downstream signalling proteins has been demonstrated
[13–16, 19, 20]. An increase in oxidative stress also seems
to be associated with MMVD [20].
The studies analysed varied significantly in terms of
their size and design.
The three studies that analysed biomolecular mech-
anisms leading to MMVD have several limitations
that should be highlighted. First, MMVP was only
diagnosed histologically in one study [19]. Further-
more, the control group consisted of cardiac trans-
plant recipients. Although their mitral valves showed
no visual pathological changes, MMVD was not previ-
ously excluded [19, 20].
Myxomatous mitral valve disease appears to be the
result of multiple genetic pathways.
Conclusion
Large scale, multicentre segregation of MMVD patients
and subsequent genome-wide association studies may
allow the identification of additional relevant genes and
Table 2 Provides a detailed overview about known genetic findings in MMVD
Disse et al. [13] Freed et al. [15] Nesta et al. [14] Monteleone et al. [18];
Lardeux [17]; Kyndt [16]
Underlying disease MMVD MVP MVP Myxomatous valvular
dystrophy + hemophilia
type A
No° of included individuals
(echocardiography + genetics)
64 28 (11 m, 17f) 43 92
Mean age (years) 49 34 55 32
Affected individuals
(positive in genetic testing) (%)
25 (39%) 12 (43%) 9 (21%) 21 (23%)
MR present 23 10 (3 m,7f) 9 (5 m,4f) 38 (14 m, 24f)
- Trace to mild 15 (11 m, 4f) 8 (3 m, 5f) 7 (4 m, 3f) 20 (0 m, 20f)
- Moderate 3 (2 m, 1f) 0 1 (f) 16 (12 m, 4f)
- Severe 5 (3 m, 2f) 2 (0 m, 2f) 1 (m) 2 (2 m,0f)
Individuals with MVP 25 (39%) (16 m,9f) 12 (43%) 9 (21%) 21 (23%)
Prolapse localisation
- AML 10 0 0 16 (12 m, 4f)
- PML 5 7 (3 m, 4f) 1(f) 9 (8 m, 1f)
- Bileaflet 10 5 (1 m, 4f) 8 (5 m, 3f) n/a
Mean LVEF in MVP patients n/a 65.5% 63.7% 69 + 8% m / 72 + 6% f
Chromosome 16 11 13 X
Locus 16p12.1.-p11.2 11p15.4 13.q31.3-q32.1 Xq28
Name of Gene MMVP 1 MMVP 2 MMVP 3 XMVD
Mode of inheritance Autosomal dominant Autosomal dominant
(incomplete penetrance)
Autosomal dominant X-linked
It gives an overview of number of patients screened in each study, patients affected (i.e. positive genetic testing result), genetic mode of inheritance and gene
locus. Grade of MR and localization of leaflet prolapse display phenotype and penetrance for each gene
MR mitral regurgitation, m male, f female, MVP mitral valve prolapse, AML anterior mitral leaflet, PML posterior mitral leaflet, EF ejection fraction, No° number, n/a
not available
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further elucidation of pathways leading to the non-
syndromic bileaflet mitral valve prolapse. Given the fact
that MMVD affects young adult patients, identification of
pathways leading to the development of diffuse myxoma-
tous degeneration of leaflet tissue is of major clinical
relevance. Early preventative interventions seeking to
reduce the leaflet stress in genetically-susceptible individ-
uals could potentially stop the progression of MMVD and
prevent late valvular complications including mitral valve
regurgitation, arrhythmias and endocarditis [15]. In vitro
studies utilising surgically-excised mitral leaflet specimens
have shown that myxomatous mitral valve changes might
be pharmacologically modifiable by angiotensin receptor 2
blockers, a process which is based on modulation of
TGF-ß [21]. This observation has potential clinical
relevance in terms of the development of future pharma-
cological therapies for MMVD.
Abbreviations
AML: Anterior mitral valve leaflet; BNP: Bone morphogenetic protein;
Chr: Chromosome; ECM: Extracellular matrix; FED: Fibroelastic deficiency;
FLNA-gene: Filamin A gene; MMVD: Myxomatous mitral valve disease;
MMVP: Myxomatous mitral valve prolapse; MVP: Mitral valve prolapse;
MVR: Mitral valve regurgitation; PML: Posterior mitral leaflet; qRT-
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